
Accepted Manuscript

Tetrahydrocannabinol Does not Reduce Pain in Patients With Chronic Abdominal Pain in a Phase 2 Placebo-controlled Study

Marjan de Vries, Dagmar C.M. van Rijckevorsel, Kris C.P. Vissers, Oliver H.G. Wilder-Smith, Harry van Goor



PII: S1542-3565(16)30858-8 DOI: 10.1016/j.cgh.2016.09.147

Reference: YJCGH 54935

To appear in: Clinical Gastroenterology and Hepatology

Accepted Date: 13 September 2016

Please cite this article as: de Vries M, van Rijckevorsel DCM, Vissers KCP, Wilder-Smith OHG, van Goor H, Pain and Nociception Neuroscience Research Group, Tetrahydrocannabinol Does not Reduce Pain in Patients With Chronic Abdominal Pain in a Phase 2 Placebo-controlled Study, *Clinical Gastroenterology and Hepatology* (2016), doi: 10.1016/j.cgh.2016.09.147.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Tetrahydrocannabinol Does not Reduce Pain in Patients With Chronic

Abdominal Pain in a Phase 2 Placebo-controlled Study Marjan de Vries¹, Dagmar C M van Rijckevorsel¹, Kris C P Vissers², Oliver H G Wilder-Smith^{2,3}, and Harry van Goor¹

Pain and Nociception Neuroscience Research Group,

¹ Department of Surgery, Radboud university medical center, Nijmegen, The Netherlands,

² Department of Anesthesiology, Pain and Palliative Medicine, Radboud university medical center, Nijmegen, The Netherlands,

³ Centre for Sensory-Motor Interaction, Department of Health Sciences, Aalborg University, Aalborg, Denmark

Short title: THC in chronic abdominal pain

Abbreviations: AE= adverse event; AppLe= appetite level; CB= cannabinoid receptor; CI= confidence interval; CP= chronic pancreatitis; HADS= hospital anxiety and depression scale; NRS= numeric rating scale; PASS= pain anxiety symptom scale; PCS= pain catastrophizing scale; PGIC= patient global impression of change; PK= pharmacokinetics; PSP= postsurgical pain; RAND SF-36= quality of life short form; RCT= randomized controlled trial; THC= Δ -9-tetrahydrocannabinol; TID= three times a day; TSQM= treatment satisfaction questionnaire for medication; VAS= visual analogue scale

Corresponding author: Marjan de Vries, MSc

Department of Surgery (route 618), PO Box 9101, 6500 HB Nijmegen, The

Netherlands

Tel: 0031 (0)24 36 10903

E-mail: marjan.devries@radboudumc.nl

Grant support: The authors are supported by a grant of the European Union, the European Fund for Regional Development (EFRO) and the Province of Gelderland for this investigator-initiated study. The Investigational Medical Product was provided by Echo Pharmaceuticals, Nijmegen, The Netherlands.

Download English Version:

https://daneshyari.com/en/article/5657202

Download Persian Version:

https://daneshyari.com/article/5657202

<u>Daneshyari.com</u>